These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7663673)

  • 41. Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. II. Single and multiple oral dosing studies.
    Brouwer KR; McNamara PJ
    Drug Metab Dispos; 1989; 17(6):652-5. PubMed ID: 2575502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Uptake of the aromatic retinoids Ro 10-9359 (etretinate) and Ro 10-1670 (acitretin), its main metabolite, delivered to cultured human fibroblasts by serum proteins. Lack of evidence for perturbation of LDL catabolism.
    Carillet V; Morlière P; Mazière JC; Hüppe G; Santus R; Dubertret L
    Biochim Biophys Acta; 1990 Nov; 1055(2):102-6. PubMed ID: 2146974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of acitretin and etretinate.
    Wiegand UW; Chou RC
    J Am Acad Dermatol; 1998 Aug; 39(2 Pt 3):S25-33. PubMed ID: 9703120
    [No Abstract]   [Full Text] [Related]  

  • 44. Acitretin.
    Ortiz NE; Nijhawan RI; Weinberg JM
    Dermatol Ther; 2013; 26(5):390-9. PubMed ID: 24099069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Etretinate absorption in the in situ perfused intestinal lumen: preliminary studies in the rat.
    Zimmerman CL; Johnson KE
    Biopharm Drug Dispos; 1991; 12(1):49-57. PubMed ID: 1828179
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-performance liquid chromatography of Ro 10-9359 (tigason) and its metabolite Ro 10-1670 in human plasma.
    Besner JG; Meloche S; Leclaire R; Band P; Mailhot S
    J Chromatogr; 1982 Sep; 231(2):467-72. PubMed ID: 6215418
    [No Abstract]   [Full Text] [Related]  

  • 47. Teratogenicity of steady-state concentrations of etretinate and metabolite acitretin maintained in maternal plasma and embryo by intragastric infusion during organogenesis in the mouse: a possible model for the extended elimination phase in human therapy.
    Löfberg B; Reiners J; Spielmann H; Nau H
    Dev Pharmacol Ther; 1990; 15(1):45-51. PubMed ID: 2147001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. On metabolism and pharmacokinetics of an aromatic retinoid.
    Paravicini U; Stöckel K; MacNamara PJ; Hänni R; Busslinger A
    Ann N Y Acad Sci; 1981 Feb; 359():54-67. PubMed ID: 6942699
    [No Abstract]   [Full Text] [Related]  

  • 49. Metabolism of an aromatic retinoid Ro 10-9359 by cultured human epidermal keratinocytes.
    Kitano Y; Okada N; Nagase N
    Arch Dermatol Res; 1982; 273(3-4):327-31. PubMed ID: 6187294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.
    Gollnick H; Bauer R; Brindley C; Orfanos CE; Plewig G; Wokalek H; Hoting E
    J Am Acad Dermatol; 1988 Sep; 19(3):458-68. PubMed ID: 2971692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Teratogenicity of etretinate during early pregnancy in the rat and its correlation with maternal plasma concentrations of the drug.
    Agnish ND; Vane FM; Rusin G; DiNardo B; Dashman T
    Teratology; 1990 Jul; 42(1):25-33. PubMed ID: 2144063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of etretinate in psoriatic patients with liver fibrosis.
    Larsen FG; Nielsen-Kudsk F; Jakobsen P; Kragballe K
    Pharmacol Toxicol; 1989 Nov; 65(5):393-7. PubMed ID: 2533684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis.
    Lauharanta J; Geiger JM
    Br J Dermatol; 1989 Jul; 121(1):107-12. PubMed ID: 2527054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Retinoids in psoriasis and disorders of keratinization.
    Fritsch PO
    J Am Acad Dermatol; 1992 Dec; 27(6 Pt 2):S8-14. PubMed ID: 1460124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatic enzyme induction potential of acitretin in male and female Sprague-Dawley rats.
    Small DS; McNamara PJ
    J Pharm Sci; 1994 May; 83(5):662-7. PubMed ID: 8071817
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biotransformation of etretinate and developmental toxicity of etretin and other aromatic retinoids in teratogenesis bioassays.
    Kochhar DM; Penner JD; Minutella LM
    Drug Metab Dispos; 1989; 17(6):618-24. PubMed ID: 2575497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Etretinate: effect of milk intake on absorption.
    DiGiovanna JJ; Gross EG; McClean SW; Ruddel ME; Gantt G; Peck GL
    J Invest Dermatol; 1984 Jun; 82(6):636-40. PubMed ID: 6233379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acitretin (Neotigason). A review of pharmacokinetics and teratogenicity and hypothesis on metabolic pathways.
    Bouvy ML; Sturkenboom MC; Cornel MC; De Jong-Van den Berg LT; Stricker BH; Wesseling H
    Pharm Weekbl Sci; 1992 Apr; 14(2):33-7. PubMed ID: 1388261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Etretinate may work where acitretin fails.
    Bleiker TO; Bourke JF; Graham-Brown RA; Hutchinson PE
    Br J Dermatol; 1997 Mar; 136(3):368-70. PubMed ID: 9115918
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acitretin versus etretinate in severe psoriasis. A double-blind randomized Nordic multicenter study in 168 patients.
    Bjerke JR; Geiger JM
    Acta Derm Venereol Suppl (Stockh); 1989; 146():206-7. PubMed ID: 2532847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.